Level D· Scientific groundwork from lab and animal studiesAnimal StudyPubMed

Bone marrow adipose tissue expansion and bone loss in experimental chronic kidney disease is independent of altered bone marrow stromal cell lineage determination.

Promruk W., Cawthorn WP., Bourne LE., Jayash SN., Pears A., Staines KA.

Animal Study on Chronic Kidney Disease, published in Front Endocrinol (Lausanne) (2025) — summary generated from the PubMed abstract.

Open my reading list
Level D· Scientific groundwork from lab and animal studiesEvidence level of this study

Evidence from laboratory and animal studies provides groundwork for understanding mechanisms and potential before human studies continue.

  • Level A · Stronger Clinical Evidence
  • Level B · Emerging clinical evidence with positive signals
  • Level C · Early human research exploring benefits
  • Level D · Scientific groundwork from lab and animal studies
  • Emerging · Emerging topic under active research
Read the A–D evidence level guide

This page is generated from the PubMed record. The Thai description is an automated summary of bibliographic fields and the abstract, not a full translation, and is not medical advice.

Study type
Animal Study
Journal
Front Endocrinol (Lausanne) (2025)
Country
Switzerland
Reported sample size
—
Source database
PubMed
PMID
41059224
DOI
10.3389/fendo.2025.1666681

Abstract (original English)

Chronic kidney disease-mineral bone disorder is the irreversible loss of kidney function leading to altered mineral homeostasis and bone loss, commonly referred to as renal osteodystrophy. Bone marrow adipose tissue (BMAT) accumulates in clinical CKD and animal models of this disease, but the mechanism(s) responsible are unclear. This study sought to determine the relationship between BMAT distribution and bone structure and to establish whether disease progression directly affected: 1) the commitment of bone marrow mesenchymal stromal cells (BMSCs) to osteoblastic (OPC) and adipogenic (APC) precursor cells, and 2) the differentiation of BMSCs to mature adipocytes and osteoblasts. Eight-week-old male C57BL/6J mice received a diet supplemented with 0.2% adenine for ≤5 weeks to induce CKD. Control mice received the same diet without adenine. Serum biochemistries were quantified using a biochemistry analyzer and plasma hormone levels by ELISA. Bone phenotypes were evaluated by µCT. The same bones were decalcified and stained with 1% osmium tetroxide and BMAT quantified using µCT. Precursor cell populations in bone marrow were quantified by flow cytometry. The development of CKD during the early stages of the disease was confirmed by elevated serum concentrations of blood urea nitrogen and creatinine from 3-weeks' induction. After 5-weeks' induction, trabecular bone microarchitectu

What this study does not prove

  • • This study does not prove SVF is an approved treatment or a replacement for standard care.
  • • This is preclinical work; animal or laboratory results cannot be applied to humans.

Evidence level

Evidence from laboratory and animal studies provides groundwork for understanding mechanisms and potential before human studies continue.

How we grade evidence
AnimalsMaleMiceMice, Inbred C57BLRenal Insufficiency, ChronicMesenchymal Stem CellsAdipose TissueBone MarrowCell LineageChronic Kidney Disease-Mineral and Bone Disorder

Browse all related research

Filter the research library by this study's title keywords, author, or publication year.

Related research